BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/19/2025 8:32:37 AM | Browse: 2 | Download: 3
 |
Received |
|
2025-02-25 06:55 |
|
Peer-Review Started |
|
2025-03-03 00:14 |
|
First Decision by Editorial Office Director |
|
2025-04-15 02:45 |
|
Return for Revision |
|
2025-04-15 02:45 |
|
Revised |
|
2025-04-28 00:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-08-12 02:58 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-08-13 02:00 |
|
Articles in Press |
|
2025-08-13 02:00 |
|
Edit the Manuscript by Language Editor |
|
2025-08-19 01:19 |
|
Typeset the Manuscript |
|
2025-12-02 02:39 |
|
Publish the Manuscript Online |
|
2025-12-19 08:32 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Role of sodium-glucose co-transporter 2 inhibitors in liver diseases
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Prajna Anirvan, Suprabhat Giri, Sayan Malakar and Dibya Lochan Praharaj |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Suprabhat Giri, Associate Professor, DM, MD, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5, KIIT Rd, Patia, Bhubaneswar 751024, Odisha, India. supg19167@gmail.com |
| Key Words |
Sodium-glucose transporter 2 inhibitors; Dapagliflozin; Empaglifozin; Metabolic dysfunction-associated steatotic liver disease; Cirrhosis |
| Core Tip |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, primarily developed for diabetes, have shown potential benefits in managing liver conditions. Studies report improved liver enzymes, lipid profile, insulin sensitivity, and stiffness in steatotic liver disease. In patients with decompensated cirrhosis of the liver with refractory ascites, SGLT2 inhibitors reduce the need for paracentesis due to their natriuretic and diuretic effects. Emerging evidence also suggests a role in preventing hepatocellular carcinoma. However, associated adverse events necessitate careful consideration. Further research is crucial to fully understand their mechanisms, optimize treatment strategies, and establish clear clinical guidelines, especially regarding the benefit-risk ratio and combination therapies. |
| Publish Date |
2025-12-19 08:32 |
| Citation |
Anirvan P, Giri S, Malakar S, Praharaj DL. Role of sodium-glucose co-transporter 2 inhibitors in liver diseases. World J Exp Med 2025; 15(4): 106403 |
| URL |
https://www.wjgnet.com/2220-315x/full/v15/i4/106403.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i4.106403 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
